SEC Form 4 · accession 0001144204-17-021599
PLx Pharma Inc. · PLXP
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David P Luci
Director
Period of report
Jan 17, 2017
Accepted (ET)
Apr 21, 2017 · 9:30 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001497504
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| OptionsF1,F2 | $1.80 | Jan 17, 2017 | A | 275,000 | A | — | Jan 17, 2022 | Common Stock | 275,000 | 275,000 | D |
| OptionsF1,F3 | $13.93 | Apr 19, 2017 | D | 298,826 | D | Mar 18, 2014 | Mar 18, 2019 | Common Stock | 298,826 | 0 | D |
Explanation of responses
- F1Does not reflect 1-for-8 reverse split effected with respect to common stock of PLx Pharma Inc. (formerly Dipexium Pharmaceuticals, Inc.) (the "Company") on April 18, 2017.
- F2Option to purchase shares of common stock vested with respect to 137,500 shares on January 17, 2017, and with respect remaining 137,500 shares in connection with the merger (the "Merger") of a wholly-owned subsidiary of the Company with and into PLx Opco Inc. (formerly PLx Pharma Inc.).
- F3Option to purchase shares of common stock cancelled by mutual agreement of the reporting person and the Company in connection with the Merger.